* This is the Professional Version. *
- Symptoms and Signs
- Key Points
- More Information
- Resources In This Article
- Drugs Mentioned In This Article
Chronic Kidney Disease
(Chronic Renal Failure; CKD)
Chronic kidney disease (CKD) is long-standing, progressive deterioration of renal function. Symptoms develop slowly and include anorexia, nausea, vomiting, stomatitis, dysgeusia, nocturia, lassitude, fatigue, pruritus, decreased mental acuity, muscle twitches and cramps, water retention, undernutrition, peripheral neuropathies, and seizures. Diagnosis is based on laboratory testing of renal function, sometimes followed by renal biopsy. Treatment is primarily directed at the underlying condition but includes fluid and electrolyte management, erythropoietin for anemia, and often dialysis or transplantation.
CKD may result from any cause of renal dysfunction of sufficient magnitude (see Table: Major Causes of Chronic Kidney Disease). The most common causes in the US are diabetic nephropathy, followed by hypertensive nephrosclerosis and various primary and secondary glomerulopathies. Metabolic syndrome, in which hypertension and type 2 diabetes are present, is a large and growing cause of renal damage
Major Causes of Chronic Kidney Disease
CKD can be roughly categorized as diminished renal reserve, renal insufficiency, or renal failure (end-stage renal disease). Initially, as renal tissue loses function, there are few abnormalities because the remaining tissue increases its performance (renal functional adaptation); a loss of 75% of renal tissue causes a fall in GFR to only 50% of normal.
Decreased renal function interferes with the kidneys’ ability to maintain fluid and electrolyte homeostasis. Changes proceed predictably, but considerable overlap and individual variation exist. The ability to concentrate urine declines early and is followed by decreases in ability to excrete phosphate, acid, and potassium. When renal failure is advanced (GFR ≤ 10 mL/min/1.73 m2), the ability to dilute urine is lost; thus, urine osmolality is usually fixed close to that of plasma (300 to 320 mOsm/kg), and urinary volume does not respond readily to variations in water intake.
Plasma concentrations of creatinine and urea (which are highly dependent on glomerular filtration) begin a hyperbolic rise as GFR diminishes. These changes are minimal early on. When the GFR falls below 10 mL/min/1.73 m2 (normal = 100 mL/min/1.73 m2), their levels increase rapidly and are usually associated with systemic manifestations (uremia). Urea and creatinine are not major contributors to the uremic symptoms; they are markers for many other substances (some not yet well defined) that cause the symptoms.
Despite a diminishing GFR, sodium and water balance is well maintained by increased fractional excretion of sodium and a normal response to thirst. Thus, the plasma sodium concentration is typically normal, and hypervolemia is infrequent unless dietary intake of sodium or water is very restricted or excessive. Heart failure can occur due to sodium and water overload, particularly in patients with decreased cardiac reserve.
For substances whose secretion is controlled mainly through distal nephron secretion (eg, potassium), adaptation usually maintains plasma levels at normal until renal failure is advanced. Potassium-sparing diuretics, ACE inhibitors, beta-blockers, NSAIDs, cyclosporine, tacrolimus, trimethoprim/sulfamethoxazole, pentamidine, or angiotensin II receptor blockers may raise plasma potassium levels in patients with less advanced renal failure.
Abnormalities of calcium, phosphate, parathyroid hormone (PTH), and vitamin D metabolism and renal osteodystrophy can occur. Decreased renal production of calcitriol contributes to hypocalcemia. Decreased renal excretion of phosphate results in hyperphosphatemia. Secondary hyperparathyroidism is common and can develop in renal failure before abnormalities in calcium or phosphate concentrations occur. For this reason, monitoring PTH in patients with moderate CKD, even before hyperphosphatemia occurs, has been recommended.
Renal osteodystrophy (abnormal bone mineralization resulting from hyperparathyroidism, calcitriol deficiency, elevated serum phosphate, or low or normal serum calcium) usually takes the form of increased bone turnover due to hyperparathyroid bone disease (osteitis fibrosa) but can also involve decreased bone turnover due to adynamic bone disease (with increased parathyroid suppression) or osteomalacia. Calcitriol deficiency may cause osteopenia or osteomalacia.
Anemia is characteristic of moderate to advanced CKD (≥ stage 3). The anemia of CKD is normochromic-normocytic, with an Hct of 20 to 30% (35 to 40% in patients with polycystic kidney disease). It is usually caused by deficient erythropoietin production due to a reduction of functional renal mass (see Decreased Erythropoiesis). Other causes include deficiencies of iron, folate, and vitamin B12.
Patients with mildly diminished renal reserve are asymptomatic. Even patients with mild to moderate renal insufficiency may have no symptoms despite elevated BUN and creatinine. Nocturia is often noted, principally due to a failure to concentrate the urine. Lassitude, fatigue, anorexia, and decreased mental acuity often are the earliest manifestations of uremia.
With more severe renal insufficiency (eg, creatinine clearance < 10 mL/min for patients without diabetes and < 15 mL/min for those with diabetes), neuromuscular symptoms may be present, including coarse muscular twitches, peripheral sensory and motor neuropathies, muscle cramps, hyperreflexia, restless legs syndrome, and seizures (usually the result of hypertensive or metabolic encephalopathy).
Anorexia, nausea, vomiting, weight loss, stomatitis, and an unpleasant taste in the mouth are almost uniformly present. The skin may be yellow-brown. Occasionally, urea from sweat crystallizes on the skin (uremic frost). Pruritus may be especially uncomfortable. Undernutrition leading to generalized tissue wasting is a prominent feature of chronic uremia.
In advanced CKD, pericarditis and GI ulceration and bleeding are common. Hypertension is present in > 80% of patients with advanced CKD, is usually related to hypervolemia, and is occasionally the result of activation of the renin-angiotensin-aldosterone system. Heart failure caused by hypertension or coronary artery disease and renal retention of sodium and water may lead to dependent edema.
CKD is usually first suspected when serum creatinine rises. The initial step is to determine whether the renal failure is acute, chronic, or acute superimposed on chronic (ie, an acute disease that further compromises renal function in a patient with CKD—see Table: Distinguishing Acute Kidney Injury From Chronic Kidney Disease). The cause of renal failure is also determined. Sometimes determining the duration of renal failure helps determine the cause; sometimes it is easier to determine the cause than the duration, and determining the cause helps determine the duration.
Distinguishing Acute Kidney Injury From Chronic Kidney Disease
Testing includes urinalysis with examination of the urinary sediment, electrolytes, urea nitrogen, and creatinine, phosphate, calcium, and CBC. Sometimes specific serologic tests are needed to determine the cause. Distinguishing acute kidney injury from CKD is most helped by a history of an elevated creatinine level or abnormal urinalysis. Urinalysis findings depend on the nature of the underlying disorder, but broad (> 3 WBC diameters wide) or especially waxy (highly refractile) casts often are prominent in advanced renal failure of any cause.
An ultrasound examination of the kidneys is usually helpful in evaluating for obstructive uropathy and in distinguishing acute kidney injury from CKD based on kidney size. Except in certain conditions (see Table: Major Causes of Chronic Kidney Disease), patients with CKD have small shrunken kidneys (usually < 10 cm in length) with thinned, hyperechoic cortex. Obtaining a precise diagnosis becomes increasingly difficult as renal function reaches values close to those of end-stage renal disease. The definitive diagnostic tool is renal biopsy, but it is not recommended when ultrasonography indicates small, fibrotic kidneys.
Staging CKD is a way of quantifying its severity. CKD has been classified into 5 stages.
GFR (in mL/min/1.73 m2) in CKD can be estimated by: 186.3 × (serum creatinine)−1.154×(age)− 0.203. The result is multiplied by 0.742 if the patient is female and by 1.21 if the patient is African American. For female African Americans, the result is multiplied by 0.742 × 1.21 (0.898). This calculation is not very accurate for patients who are older and sedentary, very obese, or very thin. Alternatively, GFR can be estimated using the Cockcroft-Gault equation to approximate creatinine clearance; this equation tends to overestimate GFR by 10 to 40%.
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula is more accurate than the MDRD and Cockcroft and Gault formulas, particularly for patients with a GFR near normal values. The CKD-EPI equation yields fewer falsely positive results indicating chronic kidney disease and predicts outcome better than the other formulas.
Progression of CKD is predicted in most cases by the degree of proteinuria. Patients with nephrotic-range proteinuria (> 3 g/24 h or urine protein/creatinine > 3) usually have a poorer prognosis and progress to renal failure more rapidly. Progression may occur even if the underlying disorder is not active. In patients with urine protein < 1.5 g/24 h, progression usually occurs more slowly if at all. Hypertension, acidosis, and hyperparathyroidism are associated with more rapid progression as well.
Control of underlying disorders
Possible restriction of dietary protein, phosphate, and potassium
Vitamin D supplements
Treatment of anemia and heart failure
Doses of all drugs adjusted as needed
Dialysis for severely decreased GFR, uremic symptoms, or sometimes hyperkalemia or heart failure
Maintaining sodium bicarbonate level at 23 mmol/L
Underlying disorders and contributory factors must be controlled. In particular, controlling hyperglycemia in patients with diabetic nephropathy and controlling hypertension in all patients substantially slows deterioration of GFR. Recent guidelines suggest a target BP of < 140/90 mm Hg, but some authors continue to recommend about 110 to 130/ < 80 mm Hg. ACE inhibitors and angiotensin II receptor blockers decrease the rate of decline in GFR in patients with most causes of CKD, particularly those with proteinuria. Increasing evidence suggests that, compared with either drug alone, combined use of ACE inhibitors and angiotensin II receptor blockers increases incidence of complications and does not slow decline in renal function, even though combined use does reduce proteinuria more.
Activity need not be restricted, although fatigue and lassitude usually limit a patient’s capacity for exercise. Pruritus may respond to phosphate binders if serum phosphate is elevated. If patients do not respond, ultraviolet phototherapy may help.
Severe protein restriction in renal disease is controversial. However, moderate restriction (0.8 g/kg/day) is safe and easy for most patients to tolerate. Some experts recommend 0.6 g/kg/day for patients with diabetes and, for patients without diabetes, > 0.8 g/kg/day if GFR is 25 to 55 mL/min/1.73 m2 or 0.6 g/kg/day if GFR is 13 to 24 mL/min/1.73 m2. Many uremic symptoms markedly lessen when protein catabolism and urea generation are reduced. Sufficient carbohydrate and fat are given to meet energy requirements and prevent ketosis. Patients for whom < 0.8 g/kg/day has been prescribed should be closely followed by a dietician.
Because dietary restrictions may reduce necessary vitamin intake, patients should take a multivitamin containing water-soluble vitamins. Administration of vitamin A and E is unnecessary. Vitamin D in the form of 1,25-dihydroxyvitamin D (calcitriol) or its analogs should be given as indicated by PTH concentrations. Dose is determined by stage of CKD, PTH concentration, and phosphate concentrations (see Table: Target Levels for PTH and Phosphate in Chronic Kidney Disease). Target levels for calcium are 8.4 to 9.5 mg/dL (2.10 to 2.37 mmol/L); for the calcium-phosphate product, < 55 mg2/dL2.
A typical starting dose is calcitriol (or a calcitriol analog) 0.25 mcg po once/day or 1 to 4 mcg 2 times/wk. PTH levels are not corrected to normal because doing so risks precipitating adynamic bone disease.
Dietary modification may be helpful for hypertriglyceridemia. In patients with hypercholesterolemia, a statin is effective. Fibric acid derivatives (clofibrate, gemfibrozil) may increase risk of rhabdomyolysis in patients with CKD, especially if taken with statin drugs, whereas ezetimibe (which reduces cholesterol absorption) appears relatively safe. Correction of hypercholesterolemia may slow progression of the underlying renal disease and reduce coronary risk.
Water intake is restricted only when serum sodium concentration is < 135 mmol/L or there is heart failure or severe edema.
Sodium restriction of 1.5 g/day benefits patients, especially those with edema, heart failure, or hypertension.
Potassium intake is closely related to meat, vegetable, and fruit ingestion and usually does not require adjustment. However, foods (especially salt substitutes) rich in potassium should generally be avoided. Hyperkalemia is infrequent (unless there is hyporeninemic hypoaldosteronism or potassium-sparing diuretic therapy) until end-stage renal failure, when potassium intake may need to be restricted to ≤ 50 mmol/day. Mild hyperkalemia (< 6 mmol/L) can be treated by reducing potassium intake and correcting metabolic acidosis. More severe hyperkalemia (> 6 mmol/L) warrants urgent treatment.
Phosphate restriction to < 1 g/day is often sufficient to maintain phosphate level in the target range during the early phase of stages 3 and 4 CKD. However, in the later phases, phosphate binders, such as calcium salts (acetate or carbonate but avoid citrate) or non–calcium-containing phosphate binders (sevelamer) are often necessary. No more than 1500 mg/day of elemental calcium should be given as binders (2000 mg/day of total calcium; binders plus dietary calcium).
Metabolic acidosis should be treated to bring serum bicarbonate to normal (> 23 mmol/L) and help reverse or slow muscle wasting, bone loss, and progression of CKD. Acidosis can be corrected with oral alkali sources such as sodium bicarbonate or an alkaline-ash diet (primarily fruits and vegetables). Sodium bicarbonate 1 to 2 g po bid is given and amount is increased gradually until bicarbonate concentration is about 23 mmol/L or until evidence of sodium overloading prevents further therapy. If the alkaline-ash diet is used, serum potassium is monitored because fruits and vegetables contain potassium.
Anemia is a common complication of moderate to advanced CKD (≥ stage 3), and, when severe, is treated with erythropoiesis-stimulating agents (ESA), such as recombinant human erythropoietin (eg, epoetin alfa). Due to risk of cardiovascular complications, including stroke, thrombosis, and death, the lowest dose of these agents needed to keep the Hb between 10 and 11 g/dL is used. Because of increased iron utilization with stimulated erythropoiesis, iron stores must be replaced, often requiring parenteral iron. Iron concentrations, iron-binding capacity, and ferritin concentrations should be followed closely. Target transferrin saturation (TSAT), calculated by dividing serum iron by total iron binding capacity and multiplying by 100%, should be > 20%, Target ferritin in patients not on dialysis is >100 ng/mL. Transfusion should not be done unless anemia is severe (Hb < 8 g/dL) or causes symptoms.
The bleeding tendency in CKD rarely needs treatment. Cryoprecipitate, RBC transfusions, desmopressin 0.3 to 0.4 mcg/kg (20 mcg maximum) in 20 mL of isotonic saline IV over 20 to 30 min, or conjugated estrogens 2.5 to 5 mg po once/day help when needed. The effects of these treatments last 12 to 48 h, except for conjugated estrogens , which may last for several days.
Symptomatic heart failure is treated with sodium restriction and diuretics. If left ventricular function is depressed, ACE inhibitors and beta-blockers (carvedilol or metoprolol) should be used. Digoxin may be added, but the dosage must be reduced. Diuretics such as furosemide usually are effective even when renal function is markedly reduced, although large doses may be needed.
Moderate or severe hypertension should be treated to avoid its deleterious effects on cardiac and renal function. Patients who do not respond to sodium restriction (1.5 g/day), should receive diuretic therapy (furosemide 80 to 240 mg po bid). Hydrochlorothiazide 12.5 mg (starting dose) to 25 mg (rarely up to 50 mg) po once/day or metolazone 5 to 10 mg po once/day or bid may be added to high-dose furosemide therapy if hypertension or edema is not controlled. Even in renal failure, the combination of a thiazide diuretic with a loop diuretic is quite potent and must be used with caution to avoid overdiuresis.
Occasionally, dialysis may be required to control heart failure. If reduction of the ECF volume does not control BP, conventional antihypertensives are added. Azotemia may increase with such treatment and may be necessary for adequate control of heart failure and/or hypertension.
Renal excretion of drugs is often impaired in patients with renal failure. Common drugs that require revised dosing include penicillins, cephalosporins, aminoglycosides, fluoroquinolones, vancomycin, and digoxin. Hemodialysis reduces the serum concentrations of some drugs, which should be supplemented after hemodialysis. It is strongly recommended that physicians consult a reference on drug dosing in renal failure before prescribing drugs to these very vulnerable patients. Some appropriate references include CKD and Drug Dosing: Information for Providers , Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO), and Drug Dosing Adjustments in Patients with Chronic Kidney Disease. Most experts avoid non-steroidal antiinflammatory drugs in patients with CKD because they may worsen renal function,
Certain drugs should be avoided entirely in patients with chronic kidney disease. They include nitrofurantoin, metformin, and phenazopyridine. The MRI contrast agent gadolinium has been associated with the development of nephrogenic systemic fibrosis in some patients; because risk is particularly high if patients have estimated GFR < 30mL/min/1.73m2, gadolinium should be avoided whenever possible in these patients.
Dialysis is usually initiated at the onset of either of the following:
These problems typically occur when the estimated GFR reaches ≤ 10 mL/min in a patient without diabetes or ≤ 15 mL/min in a patient with diabetes; patients whose estimated GFR values are near these values should be closely monitored so that these signs and symptoms are recognized early. Dialysis is best anticipated so that preparations can be made and urgent insertion of a hemodialysis catheter can be avoided. Such preparations usually begin when the patient is in early to mid stage 4 CKD; preparation allows time for patient education, selection of the type of dialysis, and timely creation of an arteriovenous fistula or placement of a peritoneal dialysis catheter. (For dialysis preparation, see Hemodialysis.)
If a living kidney donor is available, better long-term outcomes occur when a patient receives the transplanted kidney early, even before beginning dialysis. Patients who are transplant candidates but have no living donor should receive a cadaveric kidney transplant as early after initiating dialysis as possible.
Common causes of CKD in the US are diabetic nephropathy (the most common), hypertensive nephrosclerosis, glomerulopathies, and metabolic syndrome.
Effects of CKD can include hypocalcemia, hyperphosphatemia, metabolic acidosis, anemia, secondary hyperparathyroidism, and renal osteodystrophy.
Distinguish CKD from acute kidney injury based on history, clinical findings, routine laboratory tests, and ultrasonography.
Control underlying disorders (eg, diabetes) and BP levels (usually with an ACE inhibitor or angiotensin II receptor blocker).
Give supplemental vitamin D and sodium bicarbonate and restrict phosphate as needed.
Treat heart failure, anemia, and other complications.
Arrange dialysis for severely decreased GFR, uremic symptoms, and sometimes hyperkalemia or heart failure.
Prepare for dialysis early whenever possible (eg, for severely decreased GFR).
Drug NameSelect Brand Names
trimethoprimNo US brand name
nitrofurantoinFURADANTIN, MACROBID, MACRODANTIN
* This is the Professional Version. *